Rift Valley Fever Virus glycoproteins, Gn and Gc, and their use

Patent metadata

Field	Value
Publication number	US-9791445-B2
Application number	US-201414166841-A
Country	US
Kind code	B2
Filing date	Jan 28, 2014
Priority date	Jan 28, 2013
Publication date	Oct 17, 2017
Grant date	Oct 17, 2017

Abstract

The present invention describes subunit vaccines containing Gn and Gc glycoproteins of the Rift Valley Fever Virus, including nucleic acids encoding such glycoproteins, host cells, vectors, and immunoreagents generated with the glycoproteins, methods of vaccination, methods of diagnosis, and kits.

First claim

We claim herein:

1. An isolated protein comprising a fusion protein containing an amino acid sequence as set forth in SEQ ID NO:4, wherein the carboxyl terminus of said SEQ ID NO:4 is operatively linked to a protease cleavage site having six carboxyl-terminal histidine residues.

2. The isolated protein of claim 1 , wherein said protein consists of an amino acid sequence as set forth in SEQ ID NO:4 operatively linked at the carboxyl terminal alanine to a protease cleavage site having six carboxyl-terminal histidine residues, and wherein said protein induces neutralizing antibodies against Rift Valley Fever Virus in a subject at primary dose.

3. The isolated protein of claim 1 , wherein the protease cleavage site is the TENT protease site of a pFastBac/CT TOPO vector.

Assignees

• Univ Kansas State

Inventors

• Richt Juergen A
• Faburay Bonto
• Wilson William

Classifications

• A61P31/14

  for RNA viruses · CPC title

• C07K14/005

  from viruses · CPC title

• C12N2760/12234

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• G01N33/56983 Primary

  Viruses · CPC title

• C12N2760/12222

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title